153 related articles for article (PubMed ID: 17041096)
1. The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling.
Ikezoe T; Nishioka C; Tasaka T; Yang Y; Komatsu N; Togitani K; Koeffler HP; Taguchi H
Mol Cancer Ther; 2006 Oct; 5(10):2522-30. PubMed ID: 17041096
[TBL] [Abstract][Full Text] [Related]
2. Effect of SU11248 on gastrointestinal stromal tumor-T1 cells: enhancement of growth inhibition via inhibition of 3-kinase/Akt/mammalian target of rapamycin signaling.
Ikezoe T; Yang Y; Nishioka C; Bandobashi K; Nakatani H; Taguchi T; Koeffler HP; Taguchi H
Cancer Sci; 2006 Sep; 97(9):945-51. PubMed ID: 16916320
[TBL] [Abstract][Full Text] [Related]
3. Blockade of MEK/ERK signaling enhances sunitinib-induced growth inhibition and apoptosis of leukemia cells possessing activating mutations of the FLT3 gene.
Nishioka C; Ikezoe T; Yang J; Takeshita A; Taniguchi A; Komatsu N; Togitani K; Koeffler HP; Yokoyama A
Leuk Res; 2008 Jun; 32(6):865-72. PubMed ID: 17983653
[TBL] [Abstract][Full Text] [Related]
4. ZD6474 induces growth arrest and apoptosis of GIST-T1 cells, which is enhanced by concomitant use of sunitinib.
Yang Y; Ikezoe T; Nishioka C; Taguchi T; Zhu WG; Koeffler HP; Taguchi H
Cancer Sci; 2006 Dec; 97(12):1404-9. PubMed ID: 16995874
[TBL] [Abstract][Full Text] [Related]
5. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies.
Yee KW; Zeng Z; Konopleva M; Verstovsek S; Ravandi F; Ferrajoli A; Thomas D; Wierda W; Apostolidou E; Albitar M; O'Brien S; Andreeff M; Giles FJ
Clin Cancer Res; 2006 Sep; 12(17):5165-73. PubMed ID: 16951235
[TBL] [Abstract][Full Text] [Related]
6. Systematic combination screening reveals synergism between rapamycin and sunitinib against human lung cancer.
Li X; Tong LJ; Ding J; Meng LH
Cancer Lett; 2014 Jan; 342(1):159-66. PubMed ID: 24018642
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells.
Ikezoe T; Nishioka C; Bandobashi K; Yang Y; Kuwayama Y; Adachi Y; Takeuchi T; Koeffler HP; Taguchi H
Leuk Res; 2007 May; 31(5):673-82. PubMed ID: 17007924
[TBL] [Abstract][Full Text] [Related]
8. Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
Serova M; de Gramont A; Tijeras-Raballand A; Dos Santos C; Riveiro ME; Slimane K; Faivre S; Raymond E
Cancer Chemother Pharmacol; 2013 May; 71(5):1297-307. PubMed ID: 23479136
[TBL] [Abstract][Full Text] [Related]
9. Mammalian target of rapamycin as a therapeutic target in leukemia.
Giles FJ; Albitar M
Curr Mol Med; 2005 Nov; 5(7):653-61. PubMed ID: 16305491
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of mammalian target of rapamycin signaling potentiates the effects of all-trans retinoic acid to induce growth arrest and differentiation of human acute myelogenous leukemia cells.
Nishioka C; Ikezoe T; Yang J; Gery S; Koeffler HP; Yokoyama A
Int J Cancer; 2009 Oct; 125(7):1710-20. PubMed ID: 19507250
[TBL] [Abstract][Full Text] [Related]
11. Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia.
Hu S; Niu H; Minkin P; Orwick S; Shimada A; Inaba H; Dahl GV; Rubnitz J; Baker SD
Mol Cancer Ther; 2008 May; 7(5):1110-20. PubMed ID: 18483300
[TBL] [Abstract][Full Text] [Related]
12. Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248.
Potapova O; Laird AD; Nannini MA; Barone A; Li G; Moss KG; Cherrington JM; Mendel DB
Mol Cancer Ther; 2006 May; 5(5):1280-9. PubMed ID: 16731761
[TBL] [Abstract][Full Text] [Related]
13. Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab.
Wanner K; Hipp S; Oelsner M; Ringshausen I; Bogner C; Peschel C; Decker T
Br J Haematol; 2006 Sep; 134(5):475-84. PubMed ID: 16856892
[TBL] [Abstract][Full Text] [Related]
14. Potential biomarkers for the therapeutic efficacy of sorafenib, sunitinib and everolimus.
Nakai Y; Miyake M; Morizawa Y; Hori S; Tatsumi Y; Anai S; Onishi S; Tanaka N; Fujimoto K
Oncol Rep; 2017 Jan; 37(1):227-234. PubMed ID: 27840968
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of autophagy enhances sunitinib-induced cytotoxicity in rat pheochromocytoma PC12 cells.
Ikeda T; Ishii KA; Saito Y; Miura M; Otagiri A; Kawakami Y; Shimano H; Hara H; Takekoshi K
J Pharmacol Sci; 2013; 121(1):67-73. PubMed ID: 23269235
[TBL] [Abstract][Full Text] [Related]
16. Sunitinib induces apoptosis in pheochromocytoma tumor cells by inhibiting VEGFR2/Akt/mTOR/S6K1 pathways through modulation of Bcl-2 and BAD.
Saito Y; Tanaka Y; Aita Y; Ishii KA; Ikeda T; Isobe K; Kawakami Y; Shimano H; Hara H; Takekoshi K
Am J Physiol Endocrinol Metab; 2012 Mar; 302(6):E615-25. PubMed ID: 21878661
[TBL] [Abstract][Full Text] [Related]
17. Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells.
Rao RD; Mladek AC; Lamont JD; Goble JM; Erlichman C; James CD; Sarkaria JN
Neoplasia; 2005 Oct; 7(10):921-9. PubMed ID: 16242075
[TBL] [Abstract][Full Text] [Related]
18. Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia.
Tamburini J; Green AS; Bardet V; Chapuis N; Park S; Willems L; Uzunov M; Ifrah N; Dreyfus F; Lacombe C; Mayeux P; Bouscary D
Blood; 2009 Aug; 114(8):1618-27. PubMed ID: 19458359
[TBL] [Abstract][Full Text] [Related]
19. Mammalian target of rapamycin inhibition as therapy for hematologic malignancies.
Panwalkar A; Verstovsek S; Giles FJ
Cancer; 2004 Feb; 100(4):657-66. PubMed ID: 14770419
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of mTORC1 by RAD001 (everolimus) potentiates the effects of 1,25-dihydroxyvitamin D(3) to induce growth arrest and differentiation of AML cells in vitro and in vivo.
Yang J; Ikezoe T; Nishioka C; Ni L; Koeffler HP; Yokoyama A
Exp Hematol; 2010 Aug; 38(8):666-76. PubMed ID: 20382200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
